Changes of Serum HER-2 Extracellular Domain Levels of Pre- and Post-Surgery and Chemotherapy in Breast Cancer Patients
-
摘要: 目的 探讨乳腺癌患者手术、化疗前后血清HER2 ECD水平变化的临床意义。 方法 用双抗体夹心ELISA法（酶联免疫吸附法）检测乳腺癌患者及其配对手术、化疗前后血清HER2 ECD水平，进行统计分析。 结果 乳腺癌患者血清HER2 ECD水平与正常人和良性乳腺病患者有明显差异（P＜0.01）；手术后59 例乳腺癌患者血清HER2 ECD水平89.8%（53/59）下降，10.2%（6/59）升高，而33例良性乳腺病患者69.7%（23/33）下降，30.3%（10/33）升高, 两者差异有统计学意义（P＜0.05）；血清HER2 ECD水平升高组（8/59）对化疗反应率100.0%（8/8），而非升高组（51/59）对化疗反应率74.51%（38/51），两者无差别（P＞0.05）。 结论 动态监测乳腺癌患者血清HER2 ECD水平对评价其手术、化疗疗效有一定的临床提示意义。
-
关键词:
- 血清HER2 ECD水平 /
- 乳腺癌 /
- ELASA /
- 手术 /
- 化疗
Abstract: Objective To evaluate the clinical implication of variations in serum HER2/neu extracellular domain (ECD) levels before and after treatment of breast cancer patients． Methods Serum HER2/neu extracellular domain (ECD) levels of 59 breast cancer patients before and after surgery or chemotherapy were assayed by enzyme-linked immunosorbent assay (ELISA)． Results Significant different HER2 ECD levels were found between breast cancer and healthy women and benign mastopathia（P＜0.01）. 89.8% ( 53/59 ) of 59 breast cancer patients and 69.7% ( 23/33) of 33 benign mastopathia patients with decreasing levels of serum HER2/neu ECD after surgery showed difference between the two groups（P＜0.05）.100.0%（8/8）of patients with increasing levels of HER2 ECD （8/59）and 74.51%（38/51）of patients with non-increasing levels of HER2 ECD （51/59）responded to chemotherapy（P＞0.05）, showing no difference between the two groups. Conclusion Kinetic monitoring of the changes of serum HER-2/neu ECD levels in breast cancer patients may represent a valuable tool for evaluating clinical response to surgery and chemotherapy．-
Key words:
- Serum HER-2/neu ECD /
- Breast cancer /
- ELISA /
- Surgery /
- Chemotherapy
-
计量
- 文章访问数: 2574
- HTML全文浏览量: 18
- PDF下载量: 494
下载:
